Abstract The role of robot-assisted surgery in children remains controversial. This article aims to distil this debate into an evidence informed decision-making taxonomy; to adopt this technology (1) now, (2) later, or (3) not at all. Robot-assistance is safe, feasible and effective in selected cases as an adjunctive tool to enhance capabilities of minimally invasive surgery, as it is known today. At present, expectations of rigid multi-arm robotic systems to deliver higher quality care are over-estimated and poorly substantiated by evidence. Such systems are associated with high costs. Further comparative effectiveness evidence is needed to define the case-mix for which robotassistance might be indicated. It seems unlikely that we should expect compelling patient benefits when it is only the mode of minimally invasive surgery that differs. Only large higher-volume institutions that share the robot amongst multiple specialty groups are likely to be able to sustain higher associated costs with today's technology. Nevertheless, there is great potential for next-generation surgical robotics to enable better ways to treat childhood surgical diseases through less invasive techniques that are not possible today. This will demand customized technology for selected patient populations or procedures. Several prototype robots exclusively designed for pediatric use are already under development. Financial affordability must be a high priority to ensure clinical accessibility.
Introduction
In 1964 at the World Fair in New York, the renowned scientist and author Isaac Asimov broadly outlined his vision of future technologies. Many of these predictions have proved astoundingly accurate. Asimov had a special affinity for robotic technology and is eponymously credited with The Three Laws of Robotics. His forecast for this field was that ''robots will neither be common nor very good in 2014, but they will be in existence''. Although he has not lived to self-evaluate the exactness of his 50-year prediction for robotics, his prescient words serve as a testable statement that underpins an important topic of current debate in healthcare.
Robotic systems for minimally invasive surgery have arguably been the most dominant technology item to be proposed for use in pediatric surgery in recent years. Firstgeneration robotic platforms are multi-arm master-slave systems designed for the augmentation of existing minimally invasive surgical procedures across an indiscriminate number of surgical subspecialties. It remains uncertain what direction the diffusion trajectory of robotic surgery will follow in years to come and what its eventual fate might evolve towards.
Numerous stakeholders weigh into the debate regarding robotic surgery. These include clinicians, hospital administrators, healthcare economists, policy makers, industry, patients, parents, and others. Often these groups have competing interests and this contributes to a mixture of partisan voices that have unequal exposure to respective audiences. This article aims to distil the confusing argument about the role of robot-assistance in pediatric surgery into a decision-making taxonomy; to adopt this technology (1) now, (2) later, or (3) not at all. As scientific evidence is the great arbitrator of modern clinical practice, an evidence-based approach is used to address each of these questions in turn.
Adopt now
Trends in the literature and from national inpatient databases indicate that pediatric robot-assisted minimally invasive surgery is continuing to grow in global adoption [1] [2] [3] [4] . The pattern of uptake appears to be progressing along the early phase of the characteristic S-shaped diffusion of innovation curve [1, 5] (Fig. 1) . Numerous case reports, case series and comparative studies have unequivocally demonstrated that robotic surgery in children is safe. Initial concerns regarding potential danger relating to electronic equipment malfunction and system instability have been conciliated, with no known reports of patient harm due to these factors [1] .
Fundoplication and pyeloplasty are the standout applications at present [1] . Collectively, these procedures comprise an estimated 46 % proportion of overall volume of robotic procedures performed in children [1] . Recent meta-analyses of comparative effectiveness literature for these two procedures has identified that clinical outcomes are mostly either comparable or marginally superior to alternative techniques [6, 7] .
The spectrum of pathology encountered in pediatric surgery is epitomized by incredible variety of infrequently encountered operative indications. As a consequence of this, it is unlikely that quality comparative effectiveness evidence will ever emerge for many lower volume procedures that robot-assistance is promoted towards, such as Mitrofanoff appendicovesicostomy and excision of choledochal cyst. When unexpectedly faced with a rare and complex reconstructive procedure, it would be fair to offer surgeons the best technology that is available to enhance their operative abilities and aid them to achieve the best possible patient outcomes.
One of the most compelling arguments supporting the role of robot-assistance in minimally invasive surgery is that it offers to shift the overall technical performance curve to the right, and more broadly enables a minimally invasive approach in circumstances when it otherwise might not be offered (Fig. 2) [8] . This is supposedly due to various technological enhancements lowering the degree of difficulty for a specific procedure. Clearly there are some experts that have mastered conventional laparoscopic or thoracoscopic techniques and do not find added benefit from robot-assistance; however, these advanced skills are not universally shared. Several large North American national coding database studies have shown increasing rates of pediatric minimally invasive pyeloplasty in recent years that is attributed to the growing uptake of the robotassisted technique [2] [3] [4] . For the argument that robot-assisted surgery may ''democratize'' minimally invasive surgery, it should be regarded as an adjunct to support propagation of laparoscopy and thoracoscopy in settings where its uptake has barriers using non-robotic technology.
The ergonomic set-up of the robotic system master console is unique and offers unrivaled comfort for the surgeon. This reduces physical fatigue, discomfort and risk of musculoskeletal injury for the surgeon that in turn may Fig. 1 The theoretical S-shaped diffusion of innovation curve that is based on the seminal work of Everett Rogers [5] . A 'tipping point' region of the curve is shaded that typically represents a point of rapid and irrevocable adoption, often triggered when 15-20 % overall adoption is reached [35] Fig . 2 Conceptual representation of the perceived ability of robotassistance to shift the technical performance limit curve to the right possibly lead to improved patient outcomes by means of a less physically inhibited surgeon [9, 10] . Particularly in an aging workforce, long-term physical health benefits for the surgeon offers an incentive for use [9] .
Finally, it is hard to imagine a major item of technology that has diffused as far as robotic surgery only to later be abandoned. Institutions currently practicing pediatric robot-assisted surgery have vested reason to persist with their robotic surgery service to seek return on their considerable capital investment. Hospitals around the world are continuing to purchase new da Vinci Ò Surgical Systems (Intuitive Surgical, CA, USA) despite the major cost deterrent, suggesting that robotic surgery is here to stay even if a critical adoption mass is yet to be reached.
Dismiss
The da Vinci Ò Surgical System is a generic platform that was fundamentally designed with the adult patient in mind. Intuitive Surgical initially targeted its use towards cardiac surgery, specifically the coronary artery bypass graft procedure. Approximately, 90 % of its global clinical application usage is now in urology and gynecology for assorted organectomies [11, 12] . In general, the approach for the da Vinci Ò Surgical System has been to find a clinical need for a multi-purpose technology, rather than to specifically design a technology for a targeted clinical need. More so for pediatric surgery than any other specialty, it has been a technology and industry led ''push'' instead of a clinical need driven ''pull''. The technology isn't suited for small pediatric patients in its current form (Fig. 4) , and there are few signs of optimism that Intuitive Surgical will deliver a technological remedy to this anytime soon. Pediatric surgery is described as an ''orphan'' field for commercial scale innovation due to unappealingly small gross market capacity for which to seek profit through purposefully designed products [13] . Even amongst some adult specialties for which the technology is size appropriate, there has been a recent movement of diminished enthusiasm and even dissonance [12, [14] [15] [16] . One might interpret this disposition to be consistent with a post-peak phase of the Hype Cycle curve (Fig. 3) .
Healthcare spending is under intense pressure of budget restraints and prioritized distribution of resources. Medical care has arguably never been more expensive. Any new technology in a modern healthcare system must prove costeffectiveness to be considered viable. The cost-benefit ratio for first-generation robotic surgical systems is heavily skewed towards cost. Even if costs were neutral between robot-assisted surgery and existing alternatives, the clinical relevance of outcome benefits is questionable, even if statistically significant. Underneath the illusion of marketing hype, this new technology is not necessarily better for the patient and lacks strong empirical evidence to justify added costs [12] . The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Technology and Value Assessment Committee (TAVAC) recently published a safety and effectiveness analysis for use of the da Vinci Ò Surgical System in adult general surgery applications [12] . This detailed review drew conclusions that Fig. 3 The Gartner Hype Cycle curve is a graphical tool that represents the maturity, adoption and social application of specific technologies (Gartner Inc., CT, USA). It categories the predicted evolution of a technology into five key life cycle phases use of the da Vinci Ò Surgical System was safe but not superior compared to clinical outcomes for conventional laparoscopy [12] . Costs for procedures involving the da Vinci Ò Surgical System were found to be higher amongst all procedures [12] .
For an individual surgeon, surgical department or institution to commit to investing in establishing a hospital program, the technology must be accessible. Herein lies the major obstacle. Capital outlay costs associated with the da Vinci Ò Surgical System are enormous [12] . For all but a small number of well-financed tertiary institutions in the developed world, robotic surgery is financially inaccessible. Maintenance and consumables cost are also a funding challenge for institutions in addition to the fact that every da Vinci Ò Surgical System becomes outdated every 5-10 years as new models are released and old models threaten to become unsupported by the manufacturer [12] .
The procedural breakdown and case volume of pediatric urology and general surgery differs to adult counterpart specialties. For example, prostatectomy, cystectomy and partial nephrectomy make up a considerable portion of the overall case distribution and volume for an adult urologist. So much so, that the clinical practice of some urologists is geared to solely perform robot-assisted prostatectomies in concentrated high volume. Probably the leading example of this approach is Dr Vipul Patel of the Global Robotics Institute in Florida who has a personal series of over 6,000 robot-assisted prostatectomies. The most recent analysis of cost and hospital volume for robot-assisted prostatectomy was undertaken by Basto et al. in Victoria, Australia [17] . They found that a per hospital case volume quota of at least 140 procedures was required each year for cost to return a net positive for the public healthcare system [17] . There are few, if any, pediatric robot-assisted procedures that could be classified as high volume and reach [140 cases per hospital per annum. For the current direct and indirect financial costs of robotic surgery, necessary case volumes are not sufficient for its use to be economically sustainable in pediatric surgery, especially in centers for which da Vinci Ò Surgical Systems are not shared with other specialties.
Opportunity cost and cost inaccessibility generate important ethical debate [18] . Should something that so drastically widens healthcare inequality be endorsed [18] ? An underestimate of the capital outlay for a latest model da Vinci Ò Surgical System would be $2,000,000. For a fraction of the same amount of money a range of non-robotic equipment can be purchased to provide some of the more popular features of robotic systems, such as state-of-the-art 3D HD laparoscopic stack [19] [20] [21] , manually articulated instruments [22] and devices to facilitate intra-corporeal suturing [23] . One could also propose that expenditure of this money might better invested in a resource unlimited training strategy for non-robotic minimally invasive surgery, that might include funding for a modern multi-modal simulation laboratories and travel to recognized centers of excellence for intensive one-on-one proctorship. The rationale for this is that some highly skilled laparoscopic or thoracoscopic surgeons find little added benefit with robotassistance, and there does not seem to be any procedure that is accomplishable only with robot-assistance. Overall, this approach of investment in human training rather than technology acquisition may have more lasting permanency and broader return.
Await
As aptly described by Peters, ''similar to children, new technologies do not spring forth in mature form but, rather, require time for development and refinement'' [24] . Firstgeneration robotic systems are immature for ideal pediatric use [25, 26] . Early adopters and enthusiasts of robotic surgery no doubt see the future potential [26] . Their early buy-in contributes to a process of active engagement with the field such that various iterations can be evaluated in context, relative strengths and weaknesses can be exposed, and ongoing development can be guided towards meeting the needs of their clinical practice.
Some are waiting for more evidence to accumulate to make more informed decisions on whether to reject or accept robotic surgery. The speed of technical progress has generally exceeded the speed of scientific evaluation. Comparative effectiveness studies comprise only 14 % of the pediatric robotic surgery literature base; however, more of these informative studies are becoming available [1] . Others feel that it is not yet reasonable to compare outcomes between new versus established techniques due to disparate positions of most surgeons along respective learning curves (Fig. 5) . In this regard, more favorable evidence might be expected to appear with time, although it would be prudent to remain wary of Buxton's Law that reminds us that ''it is always too early until, unfortunately, it's suddenly too late'' [27] .
If cost was removed from the innovation-decision process, then the argument for robot-assisted surgery suddenly becomes less debatable. Healthy market competition is needed to stimulate impetus for price trajectory reversal. There are at least 20 different robotic surgical system prototypes that are being developed around the world by various academic and industry groups [28] . Each of these is in different stages of being driven forward through preclinical testing phases. One system that is close to clinical translation is the SPORT TM (Single Port Orifice Robotic Surgery) Surgical System that is being developed by Titan Medical (Titan Medical Inc., Toronto, Canada).
Advertisement on the company web page announces that this system is expected to be commercially available in late 2015 (http://www.titanmedicalinc.com). Almost simultaneously, Intuitive Surgical will be launching its own new single-port system, the da Vinci Ò Sp TM (Fig. 6) . At the time of writing, final specifications for the Sp TM system are yet to be publically available; however, the estimated port size diameter is approximately 25 mm with a required insertion length of approximately 75 mm for instrument deployment [29] .
Encouragingly, several prototype pediatric-specific robotic platforms and devices have also recently been reported. The KidsArm project based at The Hospital for Sick Children in Toronto has secured substantial funding to develop a compact single-port image-guided robotic arm for automated suture anastomosis. Ex vivo validation data for this platform has recently been presented [30] . The Smart Tissue Anastomosis Robot (STAR) is under development at the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Medical Centre in Washington DC. This surgical robot is intended to improve the quality, consistency, accuracy and efficiency of pediatric laparoscopic suturing [31] . Data from preliminary experiments on silicone phantom models indicate that in either manual or automatic mode the STAR is up to four time more consistent and five times faster at suturing than surgeons using the da Vinci Ò , and nine times faster than surgeons using conventional laparoscopic instruments [31] . A stapling tool based on the STAR concept is supposedly also under development [31] .
Procedure-specific robotic technology for pediatric surgery is emerging. A customized Smart Surgical Robot (SSR) for esophageal atresia and tracheo-esophageal fistula repair has been designed and assembled by Liu et al. at Kyushu University Hospital in Japan [32] . This robotic system is intended for use in open surgery to improve manual dexterity and visualization within the small confines of the infant hemithorax. It is configured to work within a 27 cm 3 workspace. Early pilot experiment results demonstrate proof-of-concept on dry-lab simulation tasks [32] . The Pediatric Cardiac Bioengineering Lab led by Pierre Dupont at Boston Children's Hospital is investigating the role of a robotic implant for gradual controlled apposition in long-gap oesophageal atresia [33] . The proposed device is a small lightweight motorized implant that is surgically fixed to both the proximal and distal esophageal pouches via rigid suture rings and then remains in situ 'floating' within the right mediastinum [33] . Ex vivo work on fresh porcine esophagus specimens has investigated tractional force responses with a functional prototype [33] . The prototype is currently sized for a 2-year-old child. Ongoing work will focus on challenges of miniaturization, as well as wireless powering and defining exact force requirements.
The nature of digital age technology is that of rapid advancement. Moore's Law dictates that the processing power of computers doubles every year based on the number of transistors per inch on integrated circuit boards. The earliest computers were a similar size to current da Vinci Ò Surgical Systems, and over the years have evolved to become smaller, cheaper, more accessible, and remarkably more intelligent. Progress of software for robotic surgical systems seems to have outpaced the progress of hardware components. Time needed for hardware design, new micro-motors or superior tendon biomaterials to be developed and integrated into sub-5-mm-sized instruments. On the horizon are ultimate goals of micro-or even nanobots that may wirelessly enter and exit the body in a silent but pervasive manner to accomplish surgical tasks [34] . This would represent entirely new paradigms of surgery such as the ''swallowable surgeon'' [34] . To reject and abandon first-generation rigid multi-arm robotic systems would cause serious detriment to the motivation of academic institutions and R&D groups pursuing more advanced and better-suited robotic technologies for future clinical use.
Discussion
For the surgeon, the advent of first-generation innovation in robotic surgery has been an impressive engineering achievement that changes the dynamic of an operating room and provides improved physical comfort while operating. In an unprecedented way, the surgeon and patient are distanced from one another but closely linked via a master-slave tele-robotic system. In effect, this allows the power of modern computing science to positively influence the relationship between the surgeon and patient. The result is an ability to augment the operative environment with features that overcome limitations of non-robotic minimally invasive surgery, and empower the surgeon with abilities that restore those appreciated in open surgery and even transcend physical and cognitive limits.
For the patient, the impact of first-generation robot-assisted surgery is quite unremarkable and underwhelming. Compared to conventional laparoscopic and thoracoscopic procedures that they might undergo, a robot-assisted minimally invasive procedure will replicate the same surgical steps. At the tool-tissue interface, their internal anatomy will essentially be handled and manipulated in the same fashion. Their skin incisions will be indifferent, or more likely slightly larger. Their outcomes will be more or less comparable. There are, however, many patients who will benefit from undergoing a minimally invasive procedure who otherwise would undergo an open procedure if not for robot-assistance.
It seems unlikely that we should expect compelling patient benefits when it is only the mode of minimally invasive surgery that differs, and the surgical approach and procedural steps remain indistinguishable from pre-existing operative alternatives. In this regard, rigid multi-arm robotic platforms on the market today represent more of a minimally invasive evolution than a surgical revolution. Like the automobile industry equivalent of the Ford Model T car, the legacy of first-generation surgical robots will be to have contributed to society as pioneering gateway technology that inspired generations of ongoing future development while priming stakeholder groups. There is enormous potential in the capacity of surgical robotics to breakthrough and achieve exciting new less invasive ways to better treat childhood surgical disease that are not possible today. The challenge for next-generation robotic technologies will be to target direct opportunities for clinical benefit and to exploit modern technology to enable these innovative endeavors. This will demand technology that is customized to selected patient populations or procedures. Importantly, financial affordability must be a high priority to ensure accessibility for clinical use. Much of tomorrow's translatable innovation is being conceived and incubated in laboratories today. To positively influence this process, an attitude of active interest and involvement (both critical and supportive) by the surgical end-user community is required to help drive and focus innovation in this field.
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